On June 30 Anthropic shipped Claude Science — and pointedly did not ship a new model. It is an AI workbench for scientists: the tools, packages, databases, and compute researchers already use, integrated around Opus 4.8 and producing auditable artifacts, in beta for every paid tier with discounted plans for academic and nonprofit labs and up to 50 funded 'AI for Science' projects. TechCrunch's framing is the week's most useful lens: three frontier labs are now attacking the same scientific market with three different architectures, making this the cleanest natural experiment yet in how labs buy verticals.
The three plays: Anthropic goes wide — a workflow wrapper on an unchanged model, distributed through subscriptions anyone can turn on. OpenAI goes narrow — GPT-Rosalind is a gated specialist model behind enterprise trusted-access, and per The New Stack the company has disbanded OpenAI for Science as a broad effort. Google DeepMind bundles owned proprietary models — AlphaFold and Gemini for Science — into its own surface. The buyers are refusing to choose: Novo Nordisk and the Allen Institute appear on both Anthropic's customer list and OpenAI's early-access list, confirming that multi-vendor is the pharma default from day one.
This is the editorial thesis playing out in public. The model is the runtime; whoever owns the workflow, the artifacts, and the audit trail owns the application. Claude Sonnet 5, launched the same day, makes the point from below: agentic capability that recently required Opus-class models is now the baseline at mid-tier prices ($2/$10 per million tokens introductory, $3/$15 after August 31), which means raw capability is commoditizing and the durable margin migrates up to the workbench. Snowflake made the point from the side, shipping Sonnet 5 same-day inside its Cortex AI perimeter as a launch partner — the governed data layer is becoming day-zero model distribution, a real procurement alternative to direct API contracts.
The runner-up story is what happens after the workbench wins: pricing follows the work. Salesforce's Agentforce Help Agent reaches GA in July with pay-per-resolution — charged only when the agent resolves an issue end-to-end autonomously, no charge on human escalation or negative feedback, with Salesforce absorbing token-cost risk on failures. Combined with Microsoft's Service Agent GA (an action-taking agent with 70+ MCP tools inside licensing enterprises already own) and Salesforce's pending ~$3.6B Fin acquisition, support has become the first vertical where seat pricing visibly dies — because resolution is the rare outcome vendors can actually measure.
What to do with this week: CIOs should treat the science fight as the template — the same three plays (workflow wrapper, gated specialist model, proprietary-model bundle) will replay in law, finance, and engineering, and the evaluation question is who owns workflow state, artifacts, and audit, not whose model benchmarks best. Vertical-function heads negotiating support renewals should demand resolution-rate telemetry and a contractual definition of 'resolved' before outcome-priced SKUs land. SaaS investors should discount model-adjacent capability claims and price workbench ownership. And vertical-AI founders should note the uncomfortable part: when the lab decides your vertical is next, its distribution move is a subscription toggle, not a sales cycle.